Simulations Plus

What if you could design a complex workflow, then set it into motion with a single click?

What if you could design a complex workflow, then set it into motion with a single click?

If you’re working on the development of injectable therapies, then this webinar is for you

Drug-induced kidney injury remains a significant concern in pharmaceutical development, with traditional methods often falling short in predicting renal toxicity across diverse compounds and patient populations.

Introducing DILIsym® 11, the latest evolution of the industry’s leading quantitative systems toxicology (QST) platform.

Our ACAT™ model has been trusted by scientists for years, and the highly anticipated update—ACATPlus—is here.

Get a first look at game-changing new functionality that will revolutionize your PBPK/PBBM modeling.

Drug discovery scientists often believe gram scale quantities of API are required to determine CMC properties like solubility, oral absorption, salt selection, and formulation strategy.

In this webinar, Dr. Brad Stefanovic, VP, Head of Clinical Innovation at Simulations Plus, discusses how biotechs and big pharma alike can stretch their clinical trials dollars while optimizing key areas for compliance and success.

ADMET Predictor 13 is almost here—and in this webinar, you’ll see how it gives your organization the First-to-Invent Advantage! Drs. David Miller, Vice President, ADMET Cheminformatics, and Michael Lawless, Sr. Principal Scientist, Cheminformatics Solutions walk you through the latest version of the software...

The FDA has released a new roadmap outlining a path toward reducing—and ultimately replacing—animal studies in pharmaceutical development with new approach methodologies (NAMs), beginning with monoclonal antibodies.

As the market for GLP-1 agonists expands, biotech companies face both immense opportunity and fierce competition. To stand out in this evolving landscape and enhance the likelihood of acquisition or out-licensing, early-stage companies must develop a strategic, data-driven clinical development plan.

Transporters play a critical role in drug absorption, distribution, and elimination, and their involvement in drug-drug interactions (DDIs) can lead to altered drug concentrations and unexpected adverse effects that hamper the effectiveness of the treatment.

Driving the development of your obesity drug assets efficiently is critical for success

In a fast-paced industry with big budget competition, you need every tool and approach to succeed.

Model-based meta analysis (MBMA) informs key drug development decisions by integrating data, published or unpublished, from multiple studies.

Understanding and predicting drug-drug interactions (DDIs) is crucial for ensuring patient safety and improving drug product development strategies.

Every day, scientists in the pharmaceutical industry are tasked with meeting regulatory expectations while also minimizing budget spend by identifying efficiencies for faster development of safer, more effective drugs.

The number of opioid overdose deaths in the United States has continued to increase for more than two decades.